Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
Jonathan E. Rosenberg(Memorial Sloan Kettering Cancer Center), Robert Dreicer(University of Virginia), Richard Bourgon, Sanjeev Mariathasan(Kaiser Permanente San Francisco Medical Center), Matthew D. Galsky(Icahn School of Medicine at Mount Sinai), Peter H. O’Donnell(University of Chicago), Daniel Castellano(Universidad Complutense de Madrid), Petros Grivas(Seattle Cancer Care Alliance), Yohann Loriot(Institut Gustave Roussy), Michiel S. van der Heijden(Zorginstituut Nederland), Richard W. Joseph(Daiichi Sankyo (United States)), Na Cui(Shanghai University), Tom Powles(Queen Mary University of London), José Luis Perez‐Gracia(Clinica Universidad de Navarra), Jean Hoffman‐Censits(Sidney Kimmel Comprehensive Cancer Center), Daniel P. Petrylak(Yale University), Ani Sarkis Balmanoukian(Angeles Clinic and Research Institute), Dean F. Bajorin(Memorial Sloan Kettering Cancer Center), Gregg Fine(Genesys (United States)), Arjun Vasant Balar(NYU Langone Health), Garrett M. Frampton(Tech Foundation), Howard A. Burris(Deaconess Hospital), Joaquim Bellmunt(Dana-Farber Cancer Institute), Mark T. Fleming(Virginia Oncology Associates), Andrea Necchi(Vita-Salute San Raffaele University), Oyewale O. Abidoye, Christina Canil(Ottawa Hospital), Sandy Srinivas(Stanford University), Dorothee Nickles, Nancy A. Dawson(University of Maryland, Baltimore), Margitta Retz(Arbeitsgemeinschaft Urologische Onkologie)
Cited by 3,712
Related Papers
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
|Journal of Clinical Oncology|1997|5.9k
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
|Genome Medicine|2017|3.7k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k